Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | ABL2 | P42684 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171143 | 1.00 | JAK2 (0.49) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL15171260 | 0.95 | HTR6 (0.46) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL16341186 | 0.95 | HTR6 (0.46) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL31626148 | 0.94 | JAK1 (0.42) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL14797959 | 0.94 | JAK1 (0.42) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL30760777 | 0.91 | JAK2 (0.44) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL30760906 | 0.91 | JAK2 (0.44) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL30760907 | 0.91 | JAK2 (0.44) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL30760762 | 0.91 | JAK2 (0.44) | JAK2JAK1SRCEGFRHTR6 | |
| SCHEMBL18644664 | 0.88 | JAK2 (0.49) | JAK2JAK1SRCEGFRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115304606-B | Degradation agent for simultaneously targeting BTK and GSPT proteins | 清华大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-115304606-A | Degradation agent for simultaneously targeting BTK and GSPT1 proteins | 清华大学 | 2022-11-08 | — | — | CN | disclosed |
| US-10314844-B2 | Inhibitors of Bruton's tyrosine kinase | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180243311-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | JAK2 14/4885JAK1 28/4885SRC 22/4885 |
| US-10314844-B2 | Inhibitors of Bruton's tyrosine kinase | BTK, ABL1, LYN | JAK2 33/4885JAK1 46/4885SRC 8/4885 |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | JAK2 14/4885JAK1 28/4885SRC 22/4885 |
| US-20180243311-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, LYN | JAK2 33/4885JAK1 46/4885SRC 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.